One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Subscription Information
doi : 10.1016/S0085-2538(22)01043-2
Volume 103, Issue 2, February 2023, Page A2
Table of Contents
doi : 10.1016/S0085-2538(22)01044-4
Volume 103, Issue 2, February 2023, Pages A3, A5, A7, A8
In memoriam: Rashad Sami Barsoum
Saraladevi Naicker1 , Mohamed Hany Hafez2 and John H. Dirks
doi : 10.1016/j.kint.2022.12.002
Volume 103, Issue 2, February 2023, Pages 236-238
Unique problems for the design of the first trials of transplanting porcine kidneys into humans
Peter P. Reese 1,2,3 , Bruce E. Gelb 4 and Brendan Parent
doi : 10.1016/j.kint.2022.10.009
Volume 103, Issue 2, February 2023, Pages 239-242
Taking the A(llorecognition) train: connecting passenger T cells to DSA
Griffith B. Perkins 1,2 , Shane T. Grey 3,4 and P. Toby Coates
doi : 10.1016/j.kint.2022.11.011
Volume 103, Issue 2, February 2023, Pages 246-248
Uromodulin and CKD: insight into variant pathogenicity
Nora Franceschini 1 and Jonathan S. Berg
doi : 10.1016/j.kint.2022.11.018
Volume 103, Issue 2, February 2023, Pages 248-250
Toward a bona fide animal model of PLA2R1-associated membranous nephropathy: one step forward
Franck Bihl 1 and Ge �rard Lambeau
doi : 10.1016/j.kint.2022.10.020
Volume 103, Issue 2, February 2023, Pages 251-253
Good and evil, more reasons to study UPR
Reiko Inagi 1 and Sho Hasegawa
doi : 10.1016/j.kint.2022.09.015
Volume 103, Issue 2, February 2023, Pages 254-256
Does kidney transplant improve health-related quality of life for youth with chronic kidney disease?
Rebecca J. Johnson 1 and Bradley A. Warady
doi : 10.1016/j.kint.2022.10.021
Volume 103, Issue 2, February 2023, Pages 256-258
A disease-modifying approach to the treatment of IgA nephropathy targeting mucosal IgA synthesis and beyond
Rosanna Coppo
doi : 10.1016/j.kint.2022.10.019
Volume 103, Issue 2, February 2023, Pages 258-261
TIPS to decide whether to prescribe aspirin for the primary prevention of cardiovascular events in chronic kidney disease
Pavel S. Roshanov 1,2 and Amit X. Garg
doi : 10.1016/j.kint.2022.10.018
Volume 103, Issue 2, February 2023, Pages 261-263
Glomerular diseases in pregnancy: pragmatic recommendations for clinical management
Fadi Fakhouri 1 , Nora Schwotzer 1 , Gianfranca Cabiddu 2,3 , Jonathan Barratt4 , He �le`ne Legardeur 5 , Vesna Garovic 6,7 , Alejandra Orozco-Guillen 8 , Jack Wetzels9 , Eric Daugas 10,11 , Gabriella Moroni 12,13 , Marina Noris 14 , Vincent Audard 15,16 , Manuel Praga 17 , Elisa Llurba 18,19 , Gre �goire Wuerzner 1 , Rossella Attini 20 , David Desseauve 5 , Elena Zakharova 21,22 , Claudio Luders 23 , Kate Wiles 24 , Filomena Leone 25 , Shilpanjali Jesudason 26,27 , Nathalie Costedoat-Chalumeau 28,29 , Andrea Kattah 6 , Virgilia Soto-Abraham 30 , Alexandre Karras 31 , Jai Prakash 32 , Liz Lightstone33,34 , Pierre Ronco 35,36 , Claudio Ponticelli 37 , Gerald Appel 38 , Giuseppe Remuzzi 14 , Vassilis Tsatsaris39,40 and Giorgina Barbara Piccoli
doi : 10.1016/j.kint.2022.10.029
Volume 103, Issue 2, February 2023, Pages 264-281
Targeting inflammation to treat diabetic kidney disease: the road to 2030
Sandra Rayego-Mateos1,2,7 , Raul R Rodrigues-Diez 2,3,7 , Beatriz Fernandez-Fernandez 2,4,7 , Carmen Mora-Ferna �ndez 2,5 , Vanessa Marchant 1,2 , Javier Donate-Correa 2,5 , Juan F. Navarro-Gonza �lez 2,5,6,8 , Alberto Ortiz 2,4,8 and Marta Ruiz-Ortega
doi : 10.1016/j.kint.2022.10.030
Volume 103, Issue 2, February 2023, Pages 282-296
Podocyte expression of human phospholipase A2 receptor 1 causes immune-mediated membranous nephropathy in mice
Nicola M. Tomas 1 , Silke Dehde 1 , Catherine Meyer-Schwesinger 2 , Ming Huang 1 , Irm Hermans-Borgmeyer 3 , Johanna Maybaum1 , Renke Lucas 1 , Jennie L. von der Heide 1 , Oliver Kretz 1 , Sarah M.S. Ko ̈ llner 1 , Larissa Seifert 1 , Tobias B. Huber 1 and Gunther Zahner
doi : 10.1016/j.kint.2022.09.008
Volume 103, Issue 2, February 2023, Pages 297-303
CD248 induces a maladaptive unfolded protein response in diabetic kidney disease
Shruthi Krishnan 1,2,3 , Jayakumar Manoharan 1 , Hongjie Wang 4 , Dheerendra Gupta 1 , Sameen Fatima 1,2,3 , Yanfei Yu 3 , Akash Mathew 1,2,3 , Zhen Li 1 , Shrey Kohli 1 , Constantin Schwab 5 , Antje Ko ̈ rner 6 , Peter R. Mertens 7 , Peter Nawroth 8 , Khurrum Shahzad 1,2 , Michael Naumann 3 , Berend Isermann 1,2,9 and Ronald Biemann
doi : 10.1016/j.kint.2022.09.024
Volume 103, Issue 2, February 2023, Pages 304-319
Anomalous kinetics of galactose-deficient IgA incurring nephropathy revealed by cross-scale optical imaging
Meijun Si 1,2,4 , Lanqing Li 3,4 , Mengting Fang 1,2,4 , Zhiming Ye 1,2 , Xu-chao Zhang 3 , Wei Yang 3 , Liming Nie3 and Xueqing Yu
doi : 10.1016/j.kint.2022.08.038
Volume 103, Issue 2, February 2023, Pages 320-330
Hematopoietic-specific melanocortin 1 receptor signaling protects against nephrotoxic serum nephritis and mediates the beneficial effect of melanocortin therapy
Xuejing Guan 1,2,6,7 , Bohan Chen 1,2,3,7 , Deepak K. Malhotra 1 , Amira F. Gohara 4 , Lance D. Dworkin 1 and Rujun Gong
doi : 10.1016/j.kint.2022.09.025
Volume 103, Issue 2, February 2023, Pages 331-342
The oxidative phosphorylation inhibitor IM156 suppresses B-cell activation by regulating mitochondrial membrane potential and contributes to the mitigation of systemic lupus erythematosus
Joo Sung Shim 1,2,3,9 , Eun Jee Kim 2,4,9 , Lucy Eunju Lee 1 , Joon Ye Kim 2,4 , Yuri Cho 2,4 , Hanna Kim 1 , Jieun Kim 1 , Sung Hoon Jang 1 , Jimin Son 5 , Jae-Ho Cheong 6 , Aekyong Kim 1 , Beom Jin Lim 7 , Sang-Jun Ha 5,10 , Jason Jungsik Song 1,8,10 and Beom Seok Kim
doi : 10.1016/j.kint.2022.09.031
Volume 103, Issue 2, February 2023, Pages 343-356
Longitudinal assessment of the health-related quality of life of children and adolescents with chronic kidney disease
Chandana Guha 1,2 , Anita van Zwieten 1,2 , Rabia Khalid 1,2 , Siah Kim 1,2 , Amanda Walker 3 , Anna Francis 4,5,6 , Madeleine Didsbury 1 , Armando Teixeira-Pinto 1,2 , Belinda Barton 7 , Chanel Prestidge 8 , Emily Lancsar 9 , Fiona Mackie 10,11 , Joseph Kwon 12 , Kirsten Howard 1,13 , Kylie-Ann Mallitt 1,2 , Martin Howell 1,2 , Allison Jaure 1,2 , Alison Hayes 1 , Rakhee Raghunandan 1 , Stavros Petrou 12 , Suncica Lah 14 , Steven McTaggart4,6 , Jonathan C. Craig 15,16 and Germaine Wong
doi : 10.1016/j.kint.2022.09.026
Volume 103, Issue 2, February 2023, Pages 357-364
Quantitative scoring of progression in transplant glomerulopathy using digital pathology may be superior to Banff cg scoring
Zeljko Kikic1,2,9 , Benjamin A. Adam 3,9 , Anna Buxeda Porras 3 , Carmen Lefaucheur 4 , Alexandre Loupy 4 , Heinz Regele 5 , Daniel Cejka 6 , Mark Haas 7 , Robert B. Colvin 8 and Michael Mengel
doi : 10.1016/j.kint.2022.10.024
Volume 103, Issue 2, February 2023, Pages 365-377
The pathologic spectrum of adenovirus nephritis in the kidney allograft
Geetha Jagannathan 1 , Astrid Weins 2 , Emily Daniel 3 , Russel J. Crew 3 , Sidney J. Swanson 4 , Glen S. Markowitz 1 , Vivette D. D’Agati 1 , Nicole K. Andeen 5 , Helmut G. Rennke 2 and Ibrahim Batal
doi : 10.1016/j.kint.2022.10.025
Volume 103, Issue 2, February 2023, Pages 378-390
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
Jonathan Barratt 1 , Richard Lafayette2 , Jens Kristensen 3 , Andrew Stone 4 , Daniel Cattran 5 , Ju ̈ rgen Floege 6 , Vladimir Tesar 7 , Herna �n Trimarchi 8 , Hong Zhang 9 , Necmi Eren10 , Alexander Paliege 11 and Brad H. Rovin 12 ; for the NefIgArd Trial Investigators
doi : 10.1016/j.kint.2022.09.017
Volume 103, Issue 2, February 2023, Pages 391-402
Effects of aspirin on cardiovascular outcomes in patients with chronic kidney disease
Johannes F.E. Mann 1,2 , Philip Joseph 1 , Peggy Gao 1 , Prem Pais 3 , Jessica Tyrwhitt 1 , Denis Xavier 4 , Tony Dans 1 , Patricio Lopez Jaramillo 5 , Habib Gamra 6 and Salim Yusuf 1 ; on behalf of the TIPS-3 investigators
doi : 10.1016/j.kint.2022.09.023
Volume 103, Issue 2, February 2023, Pages 403-410
False positivity for PLA2R1 antibody measured by ELISA in a nephrotic patient with no membranous nephropathy
Elion Hoxha 1,4 , Linda Reinhard 1,4 , Thomas Castedello 2,5 and Jan U. Becker
doi : 10.1016/j.kint.2022.09.011
Volume 103, Issue 2, February 2023, Pages 411-415
Estimating the prevalence of chronic kidney disease while accounting for nonrandom testing with inverse probability weighting
Faizan Mazhar 1 , Arvid Sjo ̈ lander1 , Edouard L. Fu 1,2,3 , Johan A ̈ rnlo ̈ v 4 , Andrew S. Levey 5 , Josef Coresh 6 and Juan Jesus Carrero
doi : 10.1016/j.kint.2022.10.027
Volume 103, Issue 2, February 2023, Pages 416-420
A polygenic score for reduced kidney function and adverse outcomes in a cohort with chronic kidney disease
Inga Steinbrenner1 , Zhi Yu 2,3,4 , Jin Jin 5 , Ulla T. Schultheiss 1,6 , Fruzsina Kotsis 1,6 , Morgan E. Grams 4,7,8 , Josef Coresh4,7,8 , Matthias Wuttke 1,6 , GCKD Investigators 13 , Florian Kronenberg 9 , Kai-Uwe Eckardt 10,11 , Nilanjan Chatterjee 5,12 , Peggy Sekula 1 and Anna Ko ̈ ttgen
doi : 10.1016/j.kint.2022.11.013
Volume 103, Issue 2, February 2023, Pages 421-424
False-positive anti-PLA2R ELISA testing in patients with diabetes mellitus
Tiffany N. Caza 1 and Christopher P. Larsen
doi : 10.1016/j.kint.2022.11.004
Volume 103, Issue 2, February 2023, Page 425
Complementary medicine and phospholipase A2 receptor (PLA2R)–related membranous nephropathy—fortuitous or causal?
Prabhjot Kaur 1,7 , Arun Prabhahar 1,7 , Ashwani Kumar 2 , Deeksha Pal 1 , Vinod Kumar 3 , Aravind Sekar 2 , Vivekanand Jha 4,5,6 , Ritambhra Nada 2 , Jasmine Sethi 1 , Smita Divyaveer 1 , Manish Rathi 1 , Harbir Singh Kohli 1 and Raja Ramachandran
doi : 10.1016/j.kint.2022.11.008
Volume 103, Issue 2, February 2023, Pages 425-427
The authors reply
Tiffany N. Caza 1 , Prema KS Jansi 2 Patrick D. Walker 1 and Anila Abraham Kurien
doi : 10.1016/j.kint.2022.11.009
Volume 103, Issue 2, February 2023, Page 427
Kidney injury and congenital solitary functioning kidney: more research efforts are needed
Pierluigi Marzuillo 1 , Anna Di Sessa 1 , Stefano Guarino 1 and Cesare Polito
doi : 10.1016/j.kint.2022.11.016
Volume 103, Issue 2, February 2023, Pages 427-428
The authors reply
Sander Groen in ’t Woud1,2 , Loes F.M. van der Zanden 1 and Michiel F. Schreuder
doi : 10.1016/j.kint.2022.11.017
Volume 103, Issue 2, February 2023, Page 428
Corrigendum to “Ttc21b deficiency attenuates autosomal dominant polycystic kidney disease in a kidney tubular- and maturation-dependent manner.� Kidney Int. 2022;102:577–591
Wei Wang 1 , Luciane M. Silva1 , Henry H. Wang 1 , Matthew A. Kavanaugh 1 , Tana S. Pottorf 1 , Bailey A. Allard 1 , Damon T. Jacobs 1 , Rouchen Dong 1 , Joseph T. Cornelius 1 , Aakriti Chaturvedi 1 , Katherine I. Swenson-Fields 1 , Timothy A. Fields 2 , Michele T. Pritchard 3 , Madhulika Sharma 4 , Chad Slawson 5 , Darren P. Wallace 4 , James P. Calvet 5 and Pamela V. Tran
doi : 10.1016/j.kint.2022.11.015
Volume 103, Issue 2, February 2023, Page 429
Corrigendum to “Novel retinal vascular phenotypes for the potential assessment of long-term risk in living kidney donors.� Kidney Int. 2022;102:661–665
Ylenia Giarratano1 , Dan Pugh2,3 , Tariq E. Farrah 2,3 , Gabriel C. Oniscu 4 , Thomas J. MacGillivray5 , Baljean Dhillon5,6 , Neeraj Dhaun 2,3,48 and Miguel O. Bernabeu
doi : 10.1016/j.kint.2022.12.001
Volume 103, Issue 2, February 2023, Pages 429-430
Erdheim-Chester disease: hairy kidney and coated aorta
Alexander Ritter 1 , Julia Meier 1 , Florian Angst2 , Wiebke Ro ̈ sler3 and Harald Seeger
doi : 10.1016/j.kint.2022.09.016
Volume 103, Issue 2, February 2023, Page 431
The Case | A benign reason behind a malignant finding
Joyita Bharati 1,2 , Vanesa Bijol 3 , Steven Salvatore 4 , Kenar D. Jhaveri 2 and Purva Sharma
doi : 10.1016/j.kint.2022.08.016
Volume 103, Issue 2, February 2023, Pages 433-434
